Early initiation of Enstilar® in managing plaque psoriasis provides better patient outcomes

01 Oct 2021
Early-initiation-of-Enstilar--in-managing-plaque-psoriasis-provides-better-patient-outcomes
Psoriasis is characterised by well-circumscribed, erythematous, scaly plaques and can be categorised as eitherlocalised or generalised, depending on the severity of the disease and its impact on patients’ quality of life. The mainstay of treatment for localised disease includes topical therapy with corticosteroids, calcipotriene and coal tar products, while generalised psoriasis may require more advanced forms of treatment like phototherapy and systemic therapy. In this case study, Dr Preamala Gunabalasingam shares her clinical experience treating.2plaque psoriasis with a combined formulation of betamethasone dipropionate and calcipotriol monohydrate in a single spray foam (Enstilar® Foam, LEO Pharma). 

Related MIMS Drugs

Editor's Recommendations